Guerbet: Q1 2025 revenue
Q1 2025 revenue
Read the original:
Guerbet: Q1 2025 revenue
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
Vivoryon Therapeutics N.V. Signs Financing Agreementfor up to EUR 15 Million
Continued here:
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury
SEATTLE, April 24, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the reduction of ischemia-reperfusion injury (IRI), today announced that it will host a symposium during the Society for Cardiovascular Angiography and Interventions (SCAI) 2025 Scientific Sessions being held May 1-3, 2025, in Washington, D.C.
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm…
RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene
Read the original here:
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm...
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 1, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2025 financial results.
Go here to see the original:
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution.
Read the original here:
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological…
? Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
Read more from the original source:
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological...
PROCEPT BioRobotics’ Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment
See the article here:
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
New study establishes CHIPS as a foundation for engineered, vascularized, insulin-producing tissue systems New study establishes CHIPS as a foundation for engineered, vascularized, insulin-producing tissue systems
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a patient that has a condition associated with non-tuberculous mycobacteria (NTM) lung infection.
Read the rest here:
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)